Legacy Pharmaceutical Packaging Acquires Multiple Blister Production Lines from McKesson RxPak
Legacy Pharmaceutical Packaging reported it has purchased three high speed blistering and cartoning lines with serialization and aggregation capabilities from McKesson RxPak’s production facility in Memphis. The infrastructure acquisition nearly doubles Legacy’s total blister production capacity, which now stands at half a billion packs per year.
In a separate equipment investment, this summer Legacy also will add an additional new high speed bottling line, bringing the contract packager’s bottling capacity to some 600 million units per year. Additionally, the company recently incorporated two new pouching machines to help meet growing demand for tablet and capsule filling applications.
The expansion-minded moves come amid recent growth in both the Rx and OTC sectors, and in expectation of continued heightened demand per the company’s transition into a high-volume, one-stop shop providing turnkey product packaging straight through market delivery.
“This infrastructure investment is a natural evolution of the expansion plans Legacy adopted several years ago, starting with a 100,000-square-foot expansion in 2017 that added both production capabilities and warehousing capacity providing a total of 300,000 square feet,” said David Spence, CEO of Legacy Pharmaceutical Packaging. “Considering both recent growth, and that we anticipate more US base production moving forward, this was the right time to continue in a way that makes Legacy an even more versatile, dynamic and turnkey packaging partner.”
For more information, visit www.LegacyPackaging.com.